Milestone’s Long Regulatory Road Ends in Approval for Cardamyst

The FDA had previously turned back the heart rhythm nasal spray twice, once in late 2023 with a refusal to file letter and again in March this year, when it flagged manufacturing issues.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top